RxDoctor Payments Data

Helen Merrick, APRN

Family · Lewes, DENPI 1023057106

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,849in general payments, 2019–2025

Across 238 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$907
  • Daiichi Sankyo Inc.$481
  • Lilly USA, LLC$364
  • Amgen$358
  • AbbVie$274
  • Pfizer$239
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,849 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$125,563
Medicare patients
447
Services billed
1,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol24$9,532
Rosuvastatin Calcium374$4,962
Atorvastatin Calcium422$4,235
Omeprazole152$2,432
Levothyroxine Sodium275$2,428
Metoprolol Succinate133$2,152
SynthroidLevothyroxine Sodium37$1,921
Losartan Potassium160$1,879
Ventolin HfaAlbuterol Sulfate25$1,673
Albuterol Sulfate HfaAlbuterol Sulfate51$1,498
Nebivolol Hcl14$1,452
Pravastatin Sodium51$1,345
Amlodipine Besylate255$1,287
Omega-3 Acid Ethyl Esters11$1,255
Fluticasone Propionate78$1,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$32$9,53224 claims
AbbVieSynthroid$274$1,92137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.

Other family in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →